Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad)
OTCMKTS:BVNRY

Bavarian Nordic A/S 3/5/2025 Earnings Report

Bavarian Nordic A/S logo
$8.02 +0.20 (+2.56%)
As of 05/2/2025 03:28 PM Eastern
Earnings History

Bavarian Nordic A/S EPS Results

Actual EPS
$0.47
Consensus EPS
$0.40
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Bavarian Nordic A/S Revenue Results

Actual Revenue
$299.48 million
Expected Revenue
$264.06 million
Beat/Miss
Beat by +$35.42 million
YoY Revenue Growth
N/A

Bavarian Nordic A/S Announcement Details

Quarter
Date
3/5/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bavarian Nordic A/S' next earnings date is estimated for Wednesday, May 14, 2025, based on past reporting schedules.

Conference Call Resources

Bavarian Nordic A/S Earnings Headlines

Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom
May 2 at 11:30 AM | finance.yahoo.com
MHRA authorises Bavarian Nordic’s chikungunya virus vaccine
May 2 at 11:30 AM | finance.yahoo.com
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
May 3, 2025 | Stansberry Research (Ad)
Bavarian Nordic A/S: Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP)
April 17, 2025 | finanznachrichten.de
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)
April 17, 2025 | finance.yahoo.com
Bavarian Nordic gets ACIP recommendation for its chikungunya vaccine
April 17, 2025 | seekingalpha.com
See More Bavarian Nordic A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic A/S and other key companies, straight to your email.

About Bavarian Nordic A/S

Bavarian Nordic A/S (OTCMKTS:BVNRY) is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.

Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.

The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.

The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. 
View Bavarian Nordic A/S Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles